GTM Playbook for Med Spas and Aesthetics in 2027

The go-to-market motion in one picture

The whole aesthetics category compresses into a short, dense funnel: a woman between 35 and 55, household income above $75K, sees a named injector's face on Instagram, searches "lip filler" plus her city three weeks later, books a consult, converts in-chair, and then either becomes a member or evaporates. Everything a med spa GTM Playbook does is either widening the top of that funnel or preventing the evaporation at the end.

What makes this different from a normal local-services funnel is that the trust layer and the demand-capture layer are separate systems that must be built at the same time. Google Ads captures intent that already exists — someone has decided they want Botox and is choosing where. Instagram creates the trust that decides which of the eight local options gets the click and, more importantly, decides whether the consult converts at 45% or 18%. Practices that fund only the capture side buy expensive clicks that bounce off a generic landing page. Practices that fund only the trust side build a following that books nowhere.

The paid mix that actually works for a practice under $5M in revenue is roughly 70-80% of spend on Google search against treatment-plus-city long-tail terms, with the remaining 20-30% on Meta for before/after carousels and first-treatment offers. Branded-treatment keywords run somewhere in the $6-$20 CPC band depending on market density, and top-quartile operators land in the $30-$80 cost-per-booking range. Shops running generic head terms against a generic homepage routinely see $120-$200 cost-per-lead — the difference is almost never the ad copy, it's that the landing page doesn't name the treatment the searcher typed.

Meta lead-gen forms are cheaper per lead ($15-$50 is a normal band) and worse per dollar. Those leads close somewhere around 15-25%; search leads close at 35-50%, because the search lead already decided. The correct way to read that spread is not "Meta is bad" — it's that Meta's job is upstream. A Meta lead is a person who was not yet in market and now is. Treat it as a nurture asset with a 30-90 day lag, route it into an SMS sequence rather than expecting a same-week booking, and its economics stop looking broken.

The most under-built arm of that picture is the loop at the bottom. The cheapest booking any aesthetics practice will ever make is the dormant client somewhere between month nine and month fourteen — someone who already trusts the injector, already knows the price, and simply drifted. A two-touch SMS naming the client, the elapsed time, the specific treatment, and a concrete open slot converts in the high teens to high twenties. It costs effectively nothing beyond the message fee. Aesthetic Record, Boulevard, and Mangomint all ship this natively, and most operators still never turn it on.

Referral deserves the same rigor. Generic "tell a friend" cards convert under 1%. Two-sided, treatment-specific, captured at checkout via QR code — a fixed credit to the referrer and the same value off the referee's first treatment — is the version that produces real volume, because it fires at the moment of maximum satisfaction rather than three weeks later in an email nobody opens.

Who owns what across the revenue org

A med spa has a revenue org whether or not anyone calls it that, and the failure mode is that all four seats collapse onto the owner-injector. Separating them is the single highest-leverage organizational move available to a practice between $500K and $3M.

The injector owns production and personal brand. A W2 cosmetic RN injector in 2027 sits around $78K-$95K base at entry, $95K-$130K at three-to-five years, and $140K-$220K at five-plus years with a portable book — call it $42-$58/hour base equivalent at the lower end. Standard production commission runs 8-12% of net collected on treatments they personally perform. Some California practices have moved to an hourly-plus-lower-production structure to sidestep the base-cap negotiation entirely. The injector's second job, whether the comp plan admits it or not, is content: three to five reels a week showing hands, face, and voice. A named injector with 10K-50K genuinely local followers is a meaningful pipeline asset, and the practice should treat filming time as paid production time rather than something done after hours.

The front desk owns conversion. This is the most under-invested seat in every failing med spa. A coordinator paid $16/hour with no commission and no closing training is an order-taker who converts consults in the high teens. A coordinator at $22-$30/hour plus 1-2% of upsells, trained to close, converts 35-50% of consultations into same-day treatment. That gap is the entire ad budget. If a practice spends $8,000/month on Google and converts consults at 18%, it is funding its competitor's growth by teaching the market that the treatment is worth wanting and then handing the booking to whoever answers the phone better.

The medical director owns compliance. In delegating states, the retainer typically lands between $2,500 and $6,000/month for chart review and protocol oversight, often with a per-injector add-on. In physician-only states — Texas and North Carolina are the canonical examples, with parts of Florida structured similarly — the physician is the legal owner of the clinical entity and is paid through a management services agreement with the operating company. Getting this structure wrong is not a paperwork problem; it is the difference between a practice that can be sold and one that cannot.

The owner owns the P&L and the calendar. Specifically: treatment-category margin, chair utilization, and the hiring pipeline. The owner's real job in a healthy practice is making sure no single person is load-bearing.

This ownership split is not unique to Aesthetics. It maps almost exactly onto how a dental service organization or a veterinary group splits producer, coordinator, and clinical oversight, and onto the SDR/AE/CS split in a B2B org. The lesson transfers in both directions: producers should not be responsible for their own pipeline conversion, and the person who books the calendar should be compensated on what the calendar produces.

One adjacent structure worth noting — as multi-location groups and private-equity-backed platforms consolidate the category, the seats formalize further: a regional director of operations, a centralized marketing function running ads across locations, and a shared compliance officer. Single-location operators can borrow the discipline without the headcount by writing an actual RACI for these four seats even when two of them are the same person.

Metrics, targets, and realistic ranges

The metric that predicts survival better than any other is rebook rate within 60 days of first visit. Top-quartile practices are north of 75%. The industry median sits closer to 48%. Below 50%, the diagnosis is almost always the same two missing mechanisms: no next-appointment booking while the client is still in the chair, and no SMS follow-up at day 14, day 30, and day 60.

Blended CAC should land in the $150-$300 range. Above $400 blended, the Google account is leaking on generic terms, or the landing pages aren't treatment-specific, or both. Lifetime value at a healthy practice runs $3,200-$9,000 over three to five years — a Botox client at roughly $600 per visit, three visits a year, retained five years, is a $9,000 client. Against that, 3:1 LTV:CAC is the floor, not the goal; well-run operators report 5:1 and better.

Membership penetration of the active client base should reach 25-40% within eighteen months of launching a program. Under 15% means the front desk is not pitching at every consult — it is not a product problem, it is a script problem. The three-tier anchor that works is roughly $150-$199/month for a facial-and-discount tier, $299-$349 for a quarterly injectable credit plus facial, and $399-$499 for a monthly injectable credit with VIP scheduling. Three hundred members at a $300 average is over $1M in predictable annual revenue before a single one-off treatment. Members visit substantially more often and spend meaningfully more per visit than non-members, which is why penetration is worth chasing even at a discount to list.

Treatment-level margin is where the Playbook gets specific. Neurotoxin prices around $12-$18/unit in tier-1 metros, $10-$14 in tier-2, and $9-$12 in tier-3, with a typical 40-60 unit treatment landing between roughly $480 and $1,080. After landed product cost and about 3% card processing, gross margin sits in the low-to-mid seventies. HA fillers price around $700-$1,200 per syringe against a couple hundred dollars of wholesale vial cost, putting margin in the 65-72% band with most clients buying one or two syringes.

Devices are a different animal and get evaluated on capacity, not margin. Per-session margin on laser hair removal is excellent once the box is paid down, but a serious hair-removal platform is a six-figure capital item on a lease in the low thousands per month, which means the practice needs on the order of 800-1,200 sessions per year on that device to stay ahead of the note. Body contouring packages price in the low thousands for multi-area bundles, but the highest-payback contouring devices are also the most expensive, and the payback math only closes if the practice can reliably sell several packages a month. The rule that survives contact with reality: never finance a device without six months of pre-booked demand.

Retail attach is the quietest lever on the list. Professional skincare lines retail at 40-55% margin and roughly double household visit cadence. Target 15-25% of revenue from retail. A practice below 8% is leaving real money on the table — for a $1M practice, the gap between 8% and 20% retail attach is high five figures to low six figures annually at healthy margin, earned with zero additional chair time.

GLP-1 economics changed permanently. Compounded semaglutide and tirzepatide were wound down by FDA in 2025 once the shortages resolved, which ended the $199-$399/month compounded program that funded a lot of 2024 P&Ls. The 2027 version is a branded program — a medical management fee layered on top of the patient's pharmacy cost, typically through a telehealth Rx partnership. Margin lands in the 30-45% range instead of 70%+. That's a worse business and still worth running, because the GLP-1 patient is a high-frequency touchpoint who converts into injectables, skin tightening, and body contouring after significant weight loss. Model it as an acquisition channel with positive contribution margin, not as the profit center it used to be.

Where the motion breaks down

Compliance shortcuts. Still running compounded GLP-1, letting a non-physician inject in a physician-only state, skipping the good-faith exam, or delegating to an esthetician what only an RN may legally perform. The consequence is not a fine — it's state board action, a malpractice claim, or insurance non-renewal, any one of which ends the practice. Every state's delegation rules differ, and "the last place I worked did it this way" is the single most expensive sentence in the industry.

Single-injector dependency. The owner-operator nurse who is the only revenue producer. One pregnancy, one illness, one competing offer, and 80% of revenue disappears in a week. The rule is to have a second injector at 40%+ capacity *before* scaling marketing spend, not after. Scaling ads into a single-injector practice just converts money into a waitlist and a burned-out clinician.

Device debt spirals. Financing several hundred thousand dollars of lasers and contouring equipment on five-year notes at double-digit rates, based on the equipment rep's pro forma. Payments exceed device revenue by month eight. The pro forma always assumes utilization the practice has never once achieved.

Injector turnover. Annual turnover in the category runs roughly 28-42%. The exit-interview themes are consistent and fixable: a portable book and a competitor offering marginally more, never getting a day off as the only injector, and being overbooked by fifteen minutes on every Botox slot. What fixes it: honest scheduling (30 minutes for neurotoxin, 45 for filler), a written non-solicit rather than a non-compete — the enforceability picture for non-competes has gotten materially worse for employers — a real CE budget in the low thousands per year, and a defined path to lead injector or partner equity. Aesthetic nursing is one of the few roles where the employee's brand is portable, so retention has to be bought with autonomy and upside, not just base.

The discount spiral. The $99 Botox, $49 facial, $199 laser-package path brings in price shoppers who rebook at roughly 15% and permanently reprices the brand in that ZIP code. Once a practice is known for $99 Botox, it cannot charge premium per-unit pricing to anyone in its own trade area. Top operators never discount the headline treatment. They discount bundles, memberships, and second-treatment-same-visit — mechanisms that increase basket size without publishing a lower unit price.

No reactivation system. Every dormant client past day 180 is somewhere between $600 and $3,000 of evaporating lifetime value. Practices with zero reactivation motion lose 30-40% of book annually and replace it with paid acquisition at $150-$300 a head — buying back clients they already owned.

The wrong system of record. Choosing a platform built for a yoga studio, a general salon, or a full surgical practice and then living with it. Migration is an 18-30 month unwinding once photo charting, consents, memberships, and payment tokens are all entangled. Aesthetic Record and Boulevard are the two most common med-spa-appropriate choices — the former stronger on EMR and photo charting for injector-heavy practices, the latter stronger on client experience and booking for multi-modality spas with a heavy facial and wellness mix. Mangomint is the common middle ground for practices in the $500K-$2M range. Dermatology and plastics-grade platforms are correct only if a board-certified physician is performing surgical procedures on site. General-purpose wellness booking software is almost always the wrong answer for an injectables practice.

How to sequence the build

Sequence matters more than any individual tactic, because several of these moves actively harm a practice if done out of order. Repricing before auditing produces a price increase on a treatment nobody is rebooking. Scaling ads before hiring the second injector produces a waitlist and churn. Launching memberships before the front desk is trained produces a product nobody pitches.

Days 1-30 are audit-only. Pull twelve months of P&L broken out by treatment category — injectables, devices, facials, memberships, retail, GLP-1 — because the aggregate number hides which engine is actually running. Audit the ad account for average CPC, cost per lead, conversion rate, and branded-versus-non-branded mix; a suspiciously good blended CPL is usually branded search taking credit for demand the brand already had. Shadow every injector for a full day to see real pacing, consult-to-treatment conversion, and chair-time efficiency. Read the medical director agreement against the specific state's delegation rules. Change nothing about pricing or comp in this window — early changes destroy the baseline you're about to measure against.

Days 31-60 are stabilization. Launch the three-tier membership or restructure an existing one to a real anchor. Reprice neurotoxin to market; most practices are a few dollars per unit under market and have been for years, and that gap is pure margin with no volume consequence. Install the rebook-before-you-leave-the-chair rule and tie a point of front-desk commission to it. If there's single-injector dependency, start the second-injector search immediately — that hire takes 60-90 days from posting to first full week.

Days 61-90 are scale. Build the reactivation sequence at 90, 180, and 365 days; for a $1M practice this is meaningful recovered revenue in the first year alone. Rebuild the ad account around treatment-plus-city long-tail terms instead of head terms. Sync manufacturer loyalty programs into checkout — clients expect points to post automatically and notice immediately when they don't. Review rebook rate weekly; if it's under 65% by day 90, the break is in the consult or the follow-up, not the marketing.

The supporting stack should be boring and integrated: card processing at standard rates, a patient financing option with a high approval rate as a second lane alongside the traditional medical credit card, review management because Google reviews are the highest-leverage conversion asset after the ad click, a real business phone and SMS line, and an accountant who has seen an aesthetics P&L before. The pattern that generalizes across Spas of every type — med, day, and hybrid wellness — is that the system of record should own scheduling, charting, payments, memberships, and messaging in one place. Every seam between two systems is a place where a rebook silently fails to happen.

Related questions

Should a med spa hire a marketing agency or run ads in-house?

Under roughly $1M in revenue, in-house with a competent contractor managing the Google account usually wins, because agency retainers consume the entire ad budget. Above $2M, a specialist aesthetics agency earns its fee on landing page discipline and creative volume.

How many injectors does a practice need before opening a second location?

At minimum, one fully booked injector plus a second at 40%+ capacity at the original location, with the original site still profitable when the owner is absent. Opening while the owner is the only reliable producer duplicates the fragility rather than the revenue.

Is retail skincare worth the inventory carrying cost?

Yes, at 40-55% margin with essentially no chair time. The risk is over-ordering breadth rather than depth. Stock a narrow line the injectors actually recommend post-treatment, and let attach rate — not shelf appearance — drive reorders.

What happens to the GLP-1 line if a patient's insurance denies coverage?

The practice keeps the management fee and the patient moves to cash-pay pharmacy pricing, which many abandon. Build the program assuming a meaningful drop-off at the coverage decision and treat retained patients as long-cycle injectables prospects.

How should a practice handle a departing injector with a portable book?

Enforce the written non-solicit, notify the affected client list proactively with a named replacement and a transition offer, and treat the first 60 days as a reactivation campaign. Practices that stay silent lose far more of the book than practices that call first.

FAQ

What is the most profitable service line for a med spa in 2027?

Injectables — neurotoxins and HA fillers — remain the margin core at roughly 70-80% and 65-72% gross margin respectively. Devices can produce excellent per-session margin but only after the capital cost is amortized, which makes them a utilization bet rather than a margin bet. Memberships aren't the highest-margin line, but they're the most valuable because they make revenue predictable.

How do membership programs actually change the economics?

A three-tier auto-debit program in the $150-$450/month range converts episodic buyers into subscribers. Members visit meaningfully more often and spend more per visit, which raises lifetime value and lowers effective CAC across the whole book. Three hundred members at a $300 average is over $1M of predictable annual revenue that arrives before anyone walks in the door.

Is compounded semaglutide still a viable offering?

No. FDA wound down compounded semaglutide and tirzepatide in 2025 once the underlying shortages resolved. Practices still running compounded GLP-1 in 2027 are exposed to state board complaints, malpractice claims, and insurance problems. The compliant path is a branded program with a medical management fee, at 30-45% margin instead of 70%+.

What should a med spa pay a nurse injector?

Roughly $78K-$95K base at entry, $95K-$130K at three-to-five years, and $140K-$220K at five-plus years with a portable book, plus 8-12% production commission on personally performed treatments. Comp alone doesn't retain injectors — honest scheduling, real time off, a CE budget, and a path to lead injector or equity do most of the work.

Which two acquisition channels are worth building first?

Google search on treatment-plus-city long-tail terms, and reactivation SMS to dormant clients. Search captures existing intent at $30-$80 cost-per-booking for disciplined operators; reactivation converts in the high teens to high twenties at near-zero cost. Instagram is the trust layer that makes both convert better, but it is not a booking channel on its own.

How do you know the practice is healthy without a full financial review?

Two numbers. Rebook rate within 60 days of first visit should exceed 65% and ideally 75%. Membership penetration of the active client base should be 25-40%. If both are healthy, the marketing and clinical sides are functioning; if either is broken, no amount of ad spend fixes the underlying leak.

Sources

• https://americanmedspa.org/
• https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
• https://www.plasticsurgery.org/news/plastic-surgery-statistics
• https://www.aesthetic-record.com/
• https://www.joinblvd.com/
• https://www.mangomint.com/
• https://nurse.org/
• https://www.ftc.gov/legal-library/browse/rules/noncompete-rule
• https://www.bls.gov/ooh/healthcare/registered-nurses.htm
• https://aspirerewards.com/

Related on PULSE

• [How do you build the GTM playbook for a med spa (Botox + filler + laser) operator in 2027?](/knowledge/gp0144)
• [GTM Playbook for Day Spas in 2027](/knowledge/gp0340)
• [How do you build a vertical SaaS for salons and spas (Boulevard / Mindbody) go-to-market motion in 2027?](/knowledge/gp0077)